DEPLOYDatabase

Company

Monogram Technologies

Monogram Technologies (formerly Monogram Orthopedics) was an AI-driven orthopedic robotics company developing the mBos TKA System, a hands-free robotic surgery…

Track Monogram Technologies
Founded
2015
HQ
unknown
Status
Zimmer Biomet subsidiary (acquired Oct 7 2025; formerly NASDAQ: MGRM)

The verified answer

As of Aug 2026, DEPLOY verifies Monogram Technologies: 1 model. 3 sources back the record.

Regulatory status1 FDA 510(k) clearance

Monogram Technologies holds 1 FDA 510(k) clearance, per the DEPLOY registry.

See all 1 filings
PublicNASDAQ: MGRM

CategorySurgical robots

Models

1

Overview

Monogram Technologies (formerly Monogram Orthopedics) was an AI-driven orthopedic robotics company developing the mBos TKA System, a hands-free robotic surgery platform for total knee arthroplasty combining 3D printing with navigated surgical robotics. Founded by CEO Benjamin Sexson, the company was acquired by Zimmer Biomet in October 2025 for $177 million, expanding Zimmer Biomet's robotics portfolio with autonomous surgical capabilities.

Verified record

Verified deployments
None on file
Active incidents
None on file

Key facts

Product

mBos TKA System (total knee arthroplasty robotic surgery)

Boundary

AI-primary autonomous cutting (robot cuts, not surgeon) - the autonomy-boundary case vs surgeon-controlled Mako/CORI/ROSA.

Corporate

ZB subsidiary since Oct 2025; founder Doug Unis = CMO not CEO (pre-acquisition CEO Benjamin Sexson).

Original company name

Monogram Orthopaedics (founded 2015)

Name change

Renamed Monogram Technologies in 2024

Tickersee public companies →

NASDAQ: MGRM

Acquisition close date

October 7, 2025

CEO

Benjamin Sexson (Co-founder & CEO)

Status

Acquired by Zimmer Biomet, Oct 2025 ($177M)

Data & sources

Web sources

3

3 sources backing this record.View all →

Models (1)

View all models →

Current platform

mBos TKA System

The Monogram mBos TKA System is Monogram's robotic total-knee-arthroplasty platform, recorded in the surgical form factor as the autonomy-boundary case of the orthopedic sub-cohort: unlike the AI-augmented surgeon-controlled systems Stryker Mako, Smith+Nephew CORI, and Zimmer Biomet ROSA, where the surgeon makes the cuts, the cleared mBos is semi-autonomous, with the robotic arm executing the bone cuts itself under AI control within a surgeon-approved, patient-specific CT-based plan and active surgeon supervision. It pairs CT-based pre-operative planning and predictive navigation with a robotic arm, built on a KUKA arm, that executes optimized cutting and insertion paths for Monogram's mPress press-fit implants. The system received FDA 510(k) clearance on March 17, 2025, although the precise cleared indication wording and the K-number could not be independently verified and the semi-autonomous characterization is sourced to Zimmer Biomet and trade coverage rather than the FDA letter, which Monogram's own clearance release described more softly as robotic-assisted TKA. A separate fully-autonomous, hands-free, saw-based version is not FDA cleared and remains in development, targeted around late 2027 or 2028; its first live-patient procedure was performed on July 26, 2025 at Krishna Shalby Hospital in Ahmedabad, India under an India CDSCO approval for a 102-procedure investigation, not under US FDA, as a single index case without verified peer-reviewed outcomes. Made by Monogram Technologies, founded in 2015 as Monogram Orthopaedics by orthopedic surgeon Dr. Doug Unis, who is chief medical officer and founder rather than chief executive, with Benjamin Sexson as the pre-acquisition CEO, and renamed Monogram Technologies in May 2024 trading on NASDAQ as MGRM, the company was acquired by Zimmer Biomet with the deal closing October 7, 2025 at about 168 million dollars enterprise value plus contingent value rights, making Monogram a Zimmer Biomet subsidiary with commercialization alongside Zimmer Biomet implants targeted for early 2027. The registry records the system at research maturity because it is cleared but pre-commercial with no units sold, and its headline fully-autonomous capability remains in development.

surgicalView model →

Monogram Technologies on the deployment map

View the global map

Monogram Technologies has no verified deployments on the DEPLOY registry yet. Explore the deployment map by place and type.

Free to use on your site, with a link back to DEPLOY.

No verified deployments for Monogram Technologies on the DEPLOY record yet. Track Monogram Technologies to know the moment the first one is verified.

Free to use on your site, with a link back to DEPLOY.

Explainers

Plain-language answers to the questions people ask about Monogram Technologies, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

What is Monogram mBos?
Monogram mBos (Monogram Bone Orthopedic Surgical platform) is an autonomy-boundary case within the surgical cluster from Monogram Orthopaedics. Per Agent A precision corrections: FDA-cleared March 17, 2025 for semi-autonomous version (KUKA-based robotic arm executes bone cut under AI control within surgeon-approved CT plan and supervision; the ROBOT cuts, NOT the surgeon. Structurally distinct from AI-augmented surgeon-controlled orthopedic systems like Stryker Mako + Smith+Nephew CORI + Zimmer Biomet ROSA where the SURGEON makes the cuts). Doug Unis CMO/founder (NOT CEO; pre-acquisition CEO was Benjamin Sexson). Zimmer Biomet acquired Monogram closed October 7, 2025 (~$168M EV + CVR). Fully-autonomous version NOT cleared (in development ~2027/2028; first live-patient case July 2025 India CDSCO trial, NOT US FDA; single index case with no peer-reviewed outcomes). Pre-commercial (not sold any units yet) maturity research. CRITICAL CAP-FLAG: 'semi-autonomous' is ZB/trade-sourced framing, NOT FDA-letter-verbatim (Monogram's own PR uses 'robotic-assisted TKA'). Cohort positioning: autonomy-boundary case extending the surgical cluster's architectural axes; demonstrates within-form_factor architectural-axis extension via robot-cuts-not-surgeon distinction.Read the full explainer →
Why DEPLOY surfaces Doug Unis as Monogram's CMO/founder, not CEO
Trade-press coverage of Monogram Orthopaedics (acquired by Zimmer Biomet closing October 7, 2025 for approximately $168M enterprise value plus contingent value rights) frequently identifies Doug Unis as CEO. Per Agent A primary-source verification, Unis is Monogram's CMO and founder. Pre-acquisition CEO was Benjamin Sexson. Small fact at one level. Foundational at another: the framework discipline cuts uniformly at every granularity of entity identification. Trade-press coverage that frames Doug Unis as CEO operates outside primary-source-anchored verification of the founder + CMO + pre-acquisition-CEO role distinctions. This piece documents the catch as a framework-in-action worked example: small-fact discipline + entity-identification precision + post-acquisition leadership scope cap-flagged transparently. Per DEPLOY's surgical cluster framework, Monogram operates the autonomous-execution archetype within the 4-way autonomy-boundary taxonomy (Monogram mBos KUKA robotic arm executes bone cut under AI control; the robot cuts, NOT the surgeon); the leadership correction operates at the same primary-source verification discipline as the autonomy-classification correction (semi-autonomous is ZB/trade-sourced framing, NOT FDA-letter-verbatim). Per DEPLOY's acquisition history Project B methodology pillar, the ZB × Monogram acquisition operates as the CANONICAL worked example for the contingent valuation_basis state (full_acquisition structure + contingent valuation_basis composition; ~$168M EV + CVR earnout). Per Arc A people graph substrate, the Doug Unis PersonCompany edge cross-references the acquisition record bidirectionally at cross-property authority depth.Read the full explainer →
How does DEPLOY track acquisition history state?
DEPLOY tracks acquisition history state as a five-structure taxonomy operating at relationship-graph granularity per Agent A's Arc D substrate (29 acquisitions + 20 FK-acquirer + 9 external + 7 acquired-assets typed). The structure taxonomy: full_acquisition (acquirer absorbs target entirely; target ceases as independent entity) → asset_purchase (specific assets transfer; target may continue) → acqui_hire (team transfers; assets minimal) → license_and_hire (Amazon × Covariant canonical: RFM models licensed + team transitions; Covariant remains standalone under Stinson; ~25% staff transition documented) → spac_merger (de-SPAC pattern; Sarcos → Palladyne canonical example). The four-state valuation_basis discipline: exact (SEC-disclosed or court-record) versus reported (press-release; not SEC-verifiable) versus undisclosed (transaction confirmed but valuation not disclosed) versus contingent (ZB × Monogram CVR canonical: structured contingent payment with earnout). The canonical lesson banked at validator-discipline depth: exact name match only, never alias-contains, in M&A graphs (6 acquisitions reverted from alias-contains reconciliation bug). Cap-flag-as-trust-signal operates recursively on acquisition framing.Read the full explainer →
How does DEPLOY track the 2021 ROSA ONE Brain wrong-trajectory Class I recall?
DEPLOY tracks the 2021 Zimmer Biomet ROSA ONE Brain 3.1 wrong-trajectory Class I recall at primary-source-anchored FDA-recall-database verification depth as a software_defect Class I recall within the ZB cluster's neurosurgical-platform product line. The substrate: urgent correction issued September 22, 2021 + FDA Class I designation November 2021; on reboot after an unexpected shutdown following patient registration, selecting 'clear the robotic arm' and running empty-device calibration could drive the device to an incorrect trajectory, sending a tool to the wrong brain location (stroke / serious-injury risk); 119 US devices at exact verification depth; 3 complaints (one inaccurate electrode placement); no patient injuries reported; software corrective update rolled out 2022; remediated. Root cause: software_defect (post-reboot calibration sequence could misinterpret coordinates and drive an instrument to an incorrect trajectory). The framework reads the incident at four substrate layers simultaneously: incident-recall actuarial depth per Phase 3 Dim 1 (severity=critical at primary-source-anchored verification; software_defect root cause; remediated status); within-ZB-cluster verification scope at sub-product-line granularity (ROSA ONE Brain neurosurgical platform vs ROSA Spine vs Mako orthopedic vs Monogram orthopedic per ZB cluster densest in corpus); cross-property acquisition history bidirectional compounding (ZB cluster ROSA ONE Brain retained per ZimVie spinoff 2022 vs ROSA Spine LEFT ZB in 2022 ZimVie spinoff per Agent A correction; ZB acquired Monogram closed October 7, 2025 ~$168M EV + CVR canonical contingent valuation_basis worked example per acquisition history Project B methodology pillar); software_defect root cause class with remediation discipline at primary-source-anchored verification depth. Cap-flag honest-absence at exact recall Z-number not captured from primary FDA pages; reputable-press source-quality tier per FierceBiotech + Becker's coverage of FDA recall record.Read the full explainer →

Current leadership (4)

Founders (2)

See all founders across the registry →

Safety record

No incidents on record for Monogram Technologies.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Recent coverage

Monogram Technologies in third-party press

Zimmer Biomet Completes Acquisition of Monogram Technologies

Oct 7, 2025

Zimmer Biomet inks 77M deal for Monogram and its hands-free orthopedic robot

Jul 14, 2025

Peer companies